AgileMD receives $750K BARDA contract to speed development of early warning system for COVID-19 severity
MATTER Support Startup Grant springboarded AgileMD’s eCart solution to next stage of development
May 5, 2021 – The U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has announced AgileMD as the recipient of a $750,000 contract to advance clinical decision support solutions for COVID-19. This partnership will further the development of AgileMD’s eCART clinical decision support tool as the company seeks FDA approval and conducts pilot clinical studies. AgileMD was the recipient of a MATTER Startup Support Grant in August 2020, and this partnership with BARDA builds upon this initial research. eCART is an early-warning and risk prediction system that helps clinicians to rapidly identify COVID-19 complications, including respiratory failure and shock, and efficiently deploy critical resources, including staff and equipment such as ventilators, efficiently.
The focus of the next phase of AgileMD’s effort is to accelerate the development and deployment of their clinical decision support platform, which includes the eCART tool. The tool has reduced mortality incidence, also helping hospitals more effectively allocate healthcare providers and critical care resources to save lives and improve clinician and patient safety.
BARDA accelerates the development of medical countermeasures and makes available transformative technologies and solutions that protect Americans from health security threats. The Rapidly Deployable Capabilities (RDC) team, which was formed as part of BARDA’s response to COVID-19, aims to advance the development of new technologies or implement existing diagnostic solutions to empower patient self-monitoring or remote patient monitoring by healthcare providers.
When the COVID-19 pandemic hit in the spring of 2020, MATTER quickly mobilized their community of innovators to address the challenges it created. As part of the COVID-19 Pandemic Response (CPR) initiative, MATTER identified AgileMD as one of three member startups to receive a COVID-19 Support Startup Grant. Their focus was on better aggregating and harnessing data to improve clinical decision-making. The grant was used to support an FDA EUA submission for a new version of the eCART analytic for COVID-19 deterioration prediction.
According to Dr. Dana Edelson, the co-founder and president of AgileMD and the executive medical director for rescue care & resiliency at UChicago Medicine, “The grant we received from MATTER allowed us to advance critical work related to predicting clinical deterioration risk in COVID-19 patients. Specifically, we were able to immediately apply MATTER funds to prepare for FDA submission for our newest analytic. This BARDA partnership continues that effort and will allow us to finalize regulatory work, pilot in 10 hospitals, and rapidly make available the solution to many others with the ultimate objective of improving clinical decision support and patient safety.”
This contract award #75A5012C00043 is one component of BARDA’s COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
AgileMD develops leading-edge predictive analytics and clinical decision support capabilities for hospitals which are deeply integrated into the electronic health record. AgileMD’s cloud-based engine has supported and empowered the medical decisions of more than 40,000 healthcare providers in the care of over 1,000,000 patient encounters from 130 hospitals around the country. AgileMD originated at the University of Chicago and is backed by premier startup incubators MATTER, Y-Combinator, and Rock Health. Visit www.agilemd.com for more information.
MATTER, the premier healthcare incubator and innovation hub, includes more than 300 cutting-edge startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together, the MATTER community is accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.